Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

Research suggests this combination reduces side effects and vastly improves outcomes, including weight loss, compared to GLP-1 alone ... gradually decrease the dosage until the medication ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

GLP-1 receptor agonists (like Wegovy and Mounjaro) have gained global attention for their ability to help people shed significant weight. These weight loss medications, administered via injections ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase ... 20mg subcutaneous weekly dose. Why it matters: Novo ...